Fosamprenavir and Lomitapide interaction

Fosamprenavir and Lomitapide: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Fosamprenavir (Fosamprenavir Calcium) label · effective 2026-06-30

Major

John’s wort ( Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson…

Contraindicationsnames LomitapideView label on DailyMed
Major

Coadministration with lomitapide is contraindicated due to potential for markedly increased transaminases.

Drug interactionsnames LomitapideView label on DailyMed
Moderate

Lipid Modifying Agents: HMG-CoA reductase inhibitors : Atorvastatin a Lovastatin, simvastatin Other lipid modifying agents : Lomitapide ↑Atorvastatin ↑Lovastatin ↑Simvastatin ↑Lomitapide Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 20 mg/day.

Drug interactionsnames LomitapideView label on DailyMed

From the Lomitapide (Juxtapid) label · effective 2026-01-20

Major

Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ].

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use with strong or moderate CYP3A4 inhibitors ( 4 ).

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use of moderate or strong CYP3A4 inhibitors with JUXTAPID is contraindicated [see Drug Interactions (7.1) ].

Warnings and precautionsby drug classView label on DailyMed
Major

If treatment with moderate or strong CYP3A4 inhibitors is unavoidable, JUXTAPID should be stopped during the course of treatment.

Warnings and precautionsby drug classView label on DailyMed
Major

Strong and moderate CYP3A4 inhibitors are contraindicated with JUXTAPID.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.